Response statement in relation to prostate cancer screening programme in high-risk populations

We welcome the backing of – and fully endorse - the development and implementation of a nationally integrated, risk-stratified early detection programme for prostate cancer in high-risk populations.

This can only be achieved by working in partnership with others, including the urological, radiological and general practitioner communities to improve the diagnosis and treatment of prostate cancer, and to reach those who don’t come forward for testing at present.  

There is a need for a focus on PSA testing thresholds, early testing for high-risk communities, standardising MRI protocols to improve diagnostic accuracy and the use of MRI-targeted biopsies to reduce harmful overdiagnosis.

We remain committed to the advancement of prostate cancer diagnostics and therapeutics through evidence-based research, clinical advocacy, and equitable healthcare access.

Our efforts are for all the fathers, brothers, sons, uncles, grandfathers – and their loved ones – to ensure that no one is left to rue a late diagnosis of prostate cancer ever again. We want to reduce the number of men diagnosed too late to be cured.